Physician profile

Edward Barns

Otolaryngology · Tulsa, OK

NPI 1922007988

$291.93

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$16.88

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Polynovo North America LLC $81.60 2022
Regeneron Healthcare Solutions, INC. $47.11 2022
Optinose US, INC. $36.89 2020-2021
Stryker Corporation $33.14 2019-2020
Alk-Abello, INC $21.01 2022
Glaxosmithkline, LLC. $16.88 2023 Nucala
Kowa Pharmaceuticals America, INC. $16.22 2022
Sanofi-Aventis U.S. LLC $14.06 2021
Intersect Ent, INC. $13.85 2021
Coopersurgical, INC. $11.17 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Edward Barns

$291.93

in general payments reported 2019-2025

Years
2019-2023
Top company
Polynovo North America LLC

https://glasscript.com/doctor/42084/edward-barns

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.